| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Saud A Alnaaim, Hayder M Al-Kuraishy, Mohammad Mitran Zailaie, Athanasios Alexiou, Marios Papadakis, Hebatallah M Saad, Gaber El-Saber Batih. The potential link between acromegaly and risk of acute ischemic stroke in patients with pituitary adenoma: a new perspective. Acta neurologica Belgica. 2023-08-16. PMID:37584889. |
acromegaly is an endocrine disorder due to the excess production of growth hormone (gh) from the anterior pituitary gland after closed epiphyseal growth plates. |
2023-08-16 |
2023-09-07 |
Not clear |
| L K Dzeranova, L I Lepeshkina, A S Shutova, M A Perepelova, E A Pigarova, V N Azizyan, P V Akopyan, Е G Przhialkovskaya, G A Melnichenko, N G Mokryshev. [Acromegaly in the differential diagnosis of hearing loss]. Problemy endokrinologii. vol 69. issue 2. 2023-07-14. PMID:37448269. |
acromegaly is a multifactorial neuroendocrine disease caused by hyperproduction of growth hormone (gh). |
2023-07-14 |
2023-08-14 |
Not clear |
| Tongxin Xiao, Rui Jiao, Shengmin Yang, Yi Wang, Xue Bai, Jingya Zhou, Ran Li, Linjie Wang, Hongbo Yang, Yong Yao, Kan Deng, Fengying Gong, Hui Pan, Lian Duan, Huijuan Zh. Incidence and risk factors of cancers in acromegaly: a Chinese single-center retrospective study. Endocrine. 2023-07-13. PMID:37442901. |
to evaluate the incidence of malignancies in acromegaly and to identify risk factors for newly-diagnostic cancers, especially the excessive growth hormone (gh) and insulin-like growth factor-1 (igf-1). |
2023-07-13 |
2023-08-14 |
Not clear |
| M Naveed, N Ain, T Aziz, K Javed, H Ishfaq, S Khalil, M Alharbi, A Alshammari, A F Alasmar. A pharmacophore screening approach of homeopathic phenols for a renovated design of fragment-optimized Bauhiniastatin-1 as a drug against acromegaly. European review for medical and pharmacological sciences. vol 27. issue 12. 2023-07-04. PMID:37401289. |
acromegaly is a fatal and chronic disease that is caused by the abnormal secretion of growth hormone (gh) by the pituitary adenoma or pituitary tumor, resulting in an increased circulated concentration of insulin-like growth factors 1 (igf-1), where in most of the cases it is secreted by a pituitary tumor. |
2023-07-04 |
2023-08-14 |
human |
| Mônica Gadelha, Nelma Verônica Marques, Christhiane Fialho, Cristiane Scaf, Elisa Lamback, Ximene Antunes, Erica Santos, Jaqueline Magalhães, Luiz Eduardo Wildember. Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years' single-center real-world experience. The Journal of clinical endocrinology and metabolism. 2023-06-26. PMID:37357993. |
acromegaly is a rare, chronic, debilitating disorder caused by prolonged hypersecretion of growth hormone (gh) and overproduction of insulin-like growth factor i (igf-i). |
2023-06-26 |
2023-08-14 |
Not clear |
| F Ceccato, C K Vedolin, G Voltan, G Antonelli, M Barbot, D Basso, D Regazzo, C Scaroni, G Occh. Paradoxical GH increase after oral glucose load in subjects with and without acromegaly. Journal of endocrinological investigation. 2023-06-21. PMID:37344722. |
paradoxical gh increase after oral glucose load in subjects with and without acromegaly. |
2023-06-21 |
2023-08-14 |
human |
| F Ceccato, C K Vedolin, G Voltan, G Antonelli, M Barbot, D Basso, D Regazzo, C Scaroni, G Occh. Paradoxical GH increase after oral glucose load in subjects with and without acromegaly. Journal of endocrinological investigation. 2023-06-21. PMID:37344722. |
here, we evaluated the gh profile in subjects with and without acromegaly aiming to refine the definition of gh-par. |
2023-06-21 |
2023-08-14 |
human |
| Denise Costa, Chiara Pellicano, Valeria Mercuri, Jacopo Maria Arnone, Flavio Rizzo, Giorgia Leodori, Patrizia Gargiulo, Edoardo Rosat. In acromegalic patients the serum levels of interleukin-33 and Resolvin D1 influence skin perfusion of hands: A pilot study. Microvascular research. 2023-06-15. PMID:37321455. |
acromegaly is a rare chronic disease, caused by the over-secretion of growth hormone (gh), that creates a pro-inflammatory state, but the exact mechanisms by which gh or insulin-like growth factor 1 (igf-i) act on inflammatory cells are not fully understood. |
2023-06-15 |
2023-08-14 |
Not clear |
| Sylvia L Asa, Ozgur Mete, Nicole D Riddle, Arie Perr. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1. Endocrine pathology. 2023-06-02. PMID:37268858. |
acromegaly was the presentation in 26 patients; 2 had central hyperthyroidism associated with growth hormone (gh) excess and one had significantly elevated prolactin (prl). |
2023-06-02 |
2023-08-14 |
Not clear |
| Junwei Guo, Wenhao Cao, Jinmei Luo, Rong Huang, Yi Xia. A retrospective study of the role of hypercapnia in patients with acromegaly. BMC pulmonary medicine. vol 23. issue 1. 2023-05-27. PMID:37244996. |
acromegaly is a multisystemic disease characterized by an excessive release of growth hormone (gh) and insulin-like growth factor-1. |
2023-05-27 |
2023-08-14 |
Not clear |
| Sara Sohail, Waqas Shafiq, Kashif Sajjad, Umal Azmat, Muhammad Atif Navee. Ectopic Acromegaly Secondary to Bronchial Tumour: A Case Report of Rare Occurrence. Journal of cancer & allied specialties. vol 7. issue 1. 2023-05-17. PMID:37197403. |
acromegaly is caused due to the unregulated and sustained overproduction of growth hormone (gh). |
2023-05-17 |
2023-08-14 |
Not clear |
| Nicholas Shoung, Ken K Y H. Managing Estrogen Therapy in the Pituitary Patient. Journal of the Endocrine Society. vol 7. issue 5. 2023-05-05. PMID:37143694. |
the route-dependent effects and potency of estrogen formulations are important considerations for optimizing the management of hypogonadal patients with pituitary disease, in particular gh deficiency and acromegaly. |
2023-05-05 |
2023-08-14 |
human |
| Paul Fellinger, Hannes Beiglböck, Georg Semmler, Lorenz Pfleger, Sabina Smajis, Clemens Baumgartner, Martin Gajdosik, Rodrig Marculescu, Greisa Vila, Yvonne Winhofer, Thomas Scherer, Michael Trauner, Alexandra Kautzky-Willer, Martin Krssak, Michael Krebs, Peter Wol. Increased GH/IGF-I axis activity relates with lower hepatic lipids and phosphor metabolism. The Journal of clinical endocrinology and metabolism. 2023-04-27. PMID:37104943. |
while data on acromegaly, a state of chronic growth hormone (gh)/insulin-like growth factor i(igf-i) excess, suggest an inverse relationship with intrahepatic lipid content (ihl), less is known about the impact of the gh/igf-i axis on ihl, lipid composition and phosphor metabolites in individuals without disorders of gh secretion. |
2023-04-27 |
2023-08-14 |
Not clear |
| Nunzia Prencipe, Giovanna Motta, Chiara M Crespi, Umberto Albert, Alessandro M Berton, Chiara Bona, Fabio Bioletto, Emanuele Varaldo, Daniela Cuboni, Valentina Gasco, Ezio Ghigo, Giuseppe Maina, Silvia Grottol. Psychiatric disorders and anger in patients with controlled acromegaly. Minerva endocrinology. 2023-04-06. PMID:37021924. |
acromegaly (acro) is a chronic rare disease caused by a pathological increase in growth hormone (gh) secretion. |
2023-04-06 |
2023-08-14 |
human |
| Juan Chen, Zhigao Xiang, Zhuo Zhang, Yan Yang, Kai Shu, Ting Le. Cognitive Dysfunction, an Increasingly Valued Long-Term Impairment in Acromegaly. Journal of clinical medicine. vol 12. issue 6. 2023-03-29. PMID:36983284. |
acromegaly is a chronic disease caused by the overproduction of growth hormone (gh) and accompanying insulin-like growth factor-1 (igf-1), which is often caused by gh-secreting pituitary adenomas. |
2023-03-29 |
2023-08-14 |
Not clear |
| Juan Chen, Zhigao Xiang, Zhuo Zhang, Yan Yang, Kai Shu, Ting Le. Cognitive Dysfunction, an Increasingly Valued Long-Term Impairment in Acromegaly. Journal of clinical medicine. vol 12. issue 6. 2023-03-29. PMID:36983284. |
here, we summarize the relevant literature concerning cognitive-behavioral research on acromegaly to demonstrate the impact of long-term impairment caused by gh and igf-1 on the cognitive behavior of patients. |
2023-03-29 |
2023-08-14 |
Not clear |
| Ana Filipa Martins, Mónica Santos, Francisco Rosári. Caloric restriction as a possible pitfall for persistent acromegaly follow-up - case report. BMC endocrine disorders. vol 23. issue 1. 2023-03-27. PMID:36973824. |
acromegaly diagnosis is established when plasma levels of igf-1 are increased and the oral glucose tolerance test (ogtt) with 75gr of glucose can't suppress growth hormone (gh) levels. |
2023-03-27 |
2023-08-14 |
Not clear |
| Anamil Khiyami, Neha Mehrotra, Sharini Venugopal, Hussain Mahmud, Georgios A Zenonos, Paul A Gardner, Pouneh K Fazel. IGF-1 is positively associated with BMI in patients with acromegaly. Pituitary. 2023-03-17. PMID:36930352. |
acromegaly is a disorder characterized by igf-1 excess due to autonomous gh secretion. |
2023-03-17 |
2023-08-14 |
Not clear |
| Anamil Khiyami, Neha Mehrotra, Sharini Venugopal, Hussain Mahmud, Georgios A Zenonos, Paul A Gardner, Pouneh K Fazel. IGF-1 is positively associated with BMI in patients with acromegaly. Pituitary. 2023-03-17. PMID:36930352. |
in individuals without acromegaly, igf-1 is not only influenced by gh secretion but is also sensitive to other factors including nutritional status, as evidenced by the inverted u-shaped association between bmi and igf-1; in low-weight individuals (bmi < 18.5 kg/m |
2023-03-17 |
2023-08-14 |
Not clear |
| Maria João Bugalho, Mariana Lopes-Pinto, Carlos Lemos, Ema Nobr. In Search of the Hyperglycemic Threshold Required to Induce Growth Hormone (GH) Suppression. Cureus. vol 15. issue 1. 2023-03-06. PMID:36874742. |
introduction according to the 2014 endocrine society clinical practice guideline on acromegaly, the confirmation of acromegaly diagnosis is established by finding a lack of suppression of growth hormone (gh) to < 1 ug/l following documented hyperglycemia during an oral glucose tolerance test. |
2023-03-06 |
2023-08-14 |
Not clear |